Thomson Reuters Announces 2009 Edition Of The CMR International Pharmaceutical R&D Factbook
Factbook Provides Authoritative Industry Metrics For The Key Stages In Drug Development
Philadelphia, PA USA, London UK. — The 2009 edition of the trusted and often cited compendium of pharmaceutical research and development statistics, the CMR International Pharmaceutical R&D Factbook, is now available. This year’s Factbook offers extended content including patent information and emerging trends in worldwide pharmaceutical R&D.
“The R&D Factbook provides the data that R&D companies need to make informed decisions,” said Dr. Jane Sharples, General Manager of CMR International. “With this publication, R&D companies can gain insights into industry dynamics and trends, determine how they perform against the market as a whole and gauge their productivity in relation to their peers and competitors. Companies can also see the consequences of adopting different R&D strategies. In short, they have accurate, independent and validated information on which to base business decisions.”
Highlights of the 2009 edition include:
• The number of new molecular entities (NME) launched onto the global market failed to improve on 2008’s 20-year low. Actual development times for new molecular entities are slowly increasing to 14 years, though major pharmaceutical companies (those that spent more than $2 billion on R&D in 2008) take on average slightly more than 11 years.
• Anti-cancer therapy is the most common area for new patent filing on emerging targets.
• India leads the way in the recent trend towards new molecular entity research by generic specialty companies.
The Centre for Medicines Research International Ltd (CMR International), a Thomson Reuters business, yearly publishes the Factbook. This is an up-to-date business planning tool for decision makers in the pharmaceutical industry, including R&D, corporate finance, business strategy, marketing planning and corporate communications professionals. Since 1994, CMR International has worked with leading global pharmaceutical and biotechnology companies to assess R&D productivity and provide insights which help organizations to improve the planning and effectiveness of R&D.
The information published in the Factbook is based on primary sources covering major pharmaceutical companies which account for approximately 80 percent of the industry’s global R&D expenditure. The CMR International 2009 Pharmaceutical R&D Factbook is available as single-user or enterprise-wide editions, in either electronic or hard copy format.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.